UNSPSC 51144601: Caffeine or trimethylxanthine

This classification denotes a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears US NIH Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate.

UNSPSC 51144601 Caffeine or trimethylxanthine is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and OTC items sourced through cooperative purchasing and direct-supply channels rather than caffeine specifically. State and local governments soliciting under this code are acquiring generic multi-source pharmaceuticals, naloxone, drug deactivation systems, and related health-supply products through competitive bidding and cooperative purchasing frameworks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The scope reflects pharmaceutical procurement at scale, with vendors expected to manage supply chain compliance including FDA registration, Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and product tracking through authorized wholesale distributors.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with bids due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct relationships between the state pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration's Office of State Procurement, released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with proposals due March 26, 2026, awarded vendors to be provided to authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) by May 15, 2026, and contracts effective July 1, 2026. Vendors face significant compliance and insurance requirements, including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000, and must maintain pricing flexibility across multiple net and WAC-minus pricing structures.